Nashville, Tennessee
CNS medication trials in Nashville, TN
23 CNS medication studies are recruiting participants at sites in Nashville as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Nashville at a glance
- 23 studies are recruiting at a site in Nashville.
- By phase: Early Phase 1 (1), Phase 1 (1), Phase 2 (4), Phase 3 (15), Phase 4 (2).
- By sponsor: industry (18), university, hospital or other (5).
- By research area: Parkinson's Disease (8), Migraine (6), Epilepsy (5), Schizophrenia (2), Depression (1), Multiple Sclerosis (1).
- Most recent update to one of these records: November 17, 2026.
Depression studies recruiting in Nashville
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Yale University
- Study site
- Athena Care
- Registry record
- NCT06713616 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Nashville, TN on ClinicalTrials.gov.
Schizophrenia studies recruiting in Nashville
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- Access Clinical Trials
- Registry record
- NCT06229210 · updated
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Vanderbilt Psychiatric Hospital
- Registry record
- NCT06585787 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Nashville, TN on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Nashville
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Elliston Place Medical Oncology & Hematology ( Site 0215)
- Registry record
- NCT06623422 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- SCRI Oncology Partners ( Site 7004) · Tennessee Oncology ( Site 0018)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Nashville General Hospital ( Site 0017) · SCRI Oncology Partners ( Site 7005) · Vanderbilt-Ingram Cancer Center ( Site 0038)
- Registry record
- NCT06966700 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT07174310 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- Vanderbilt University
- Registry record
- NCT06680830 · updated
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
- Phase 2
- Ages 30 to 80
- All sexes
- Sponsor
- Appello Pharmaceuticals, Inc.
- Study site
- Vanderbilt University Medical Center (Site #204)
- Registry record
- NCT07432958 · updated
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
- Phase 4
- Ages 50 to 85
- All sexes
- Sponsor
- Vanderbilt University Medical Center
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT05357612 · updated
[18F]F-DOPA Imaging in Patients With Autonomic Failure
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Daniel Claassen
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT04246437 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Nashville, TN on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Nashville
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Vanderbilt Breast Center at One Hundred Oaks
- Registry record
- NCT07225504 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Nashville, TN on ClinicalTrials.gov.
Epilepsy studies recruiting in Nashville
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Registry record
- NCT07594119 · updated
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT05716100 · updated
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT06798896 · updated
Effect of Rose Odor Exposure on Ictal Apnea
- Early Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Vanderbilt University Medical Center
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT07116421 · updated
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT07219407 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Nashville, TN on ClinicalTrials.gov.
Migraine studies recruiting in Nashville
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Vanderbilt Medical Center
- Registry record
- NCT06972056 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- Access Clinical Trials, Inc · Clinical Research Associates, Inc.
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- Access Clinical Trials Inc · Clinical Research Associates, Inc.
- Registry record
- NCT07674654 · updated
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- AbbVie
- Study site
- Access Clinical Trials Inc /ID# 270280
- Registry record
- NCT06810505 · updated
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- AbbVie
- Study site
- Access Clinical Trials, Inc. /ID# 248532
- Registry record
- NCT05711394 · updated
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- AbbVie
- Study site
- Access Clinical Trials, Inc. /ID# 228002
- Registry record
- NCT05125302 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Nashville, TN on ClinicalTrials.gov.
Ask about studies near Nashville
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.
CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections